Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMY64HE)

Drug Name
alpha-linolenic acid Drug Info
Synonyms
Linolenic acid; linolenic acid; alpha-Linolenic acid; 463-40-1; linolenate; (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid; a-Linolenic acid; cis,cis,cis-9,12,15-Octadecatrienoic acid; all-cis-9,12,15-Octadecatrienoic acid; alpha-Linolenate; 9-cis,12-cis,15-cis-Octadecatrienoic acid; (Z,Z,Z)-9,12,15-Octadecatrienoic acid; Linolenic acid (8CI); 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-; (9,12,15)-linolenic acid; alpha-Lnn; 9Z,12Z,15Z-Octadecatrienoic acid; Industrene 120; CCRIS 656; UNII-0RBV727H71; (9Z,12Z,15Z)-Octadecatrienoic acid; linolenate; alpha-LA; C18:3; LINOLENIC ACID
Cross-matching ID
PubChem CID
5280934
ChEBI ID
CHEMBL8739
CAS Number
CAS 463-40-1
TTD Drug ID
D0C5SV
INTEDE Drug ID
DR1988

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.01 1.11e-2 34/36 (94.44%) POLE2;LIG1;POLD2;...
Base excision repair 1.98 5.53e-3 29/33 (87.88%) POLE2;PARP2;LIG1;...
Asthma 1.95 7.38e-3 25/31 (80.65%) FCER1G;HLA-DRB1;HLA-DRA;...
Mannose type O-glycan biosynthesis 1.84 2.21e-2 14/23 (60.87%) RXYLT1;B4GAT1;B3GAT1;...
Lysine degradation 1.79 4.20e-2 51/63 (80.95%) EZH2;ALDH2;SUV39H1;...
Antigen processing and presentation 1.75 4.61e-2 60/78 (76.92%) CD74;IFI30;CALR;...
Toxoplasmosis 1.72 4.43e-2 103/112 (91.96%) MAP2K6;IFNGR1;HLA-DRB1;...
Malaria -1.95 1.37e-2 44/50 (88%) HGF;SELE;TGFB3;...
Steroid biosynthesis -1.96 2.74e-2 19/20 (95%) CYP51A1;LIPA;NSDHL;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 1.11uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.25uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 0.25uM - 1.11uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H